Strong science. Potential for very broad oncology labeling even though initial focus is restricted to B cell cancers. Any company that makes progress with multiple myeloma will be desired by BP. They have a lot going for them. Be careful if you take a stake now though - as CEO did say he'll dilute on upcoming spike from trial. Great science but financially struggling and at risk for eventual overdilution imo. They will need to partner early. Still - I am taking small stake.
Market Data 
Markets 
AI
